Transplantation of High Panel-Reactive Antibody Left Ventricular Assist Device Patients Without Crossmatch Using On-Bypass Pheresis and Alemtuzumab

Heart transplantation with plasmapheresis and alemtuzumab in HS LVAD patients, most with a positive crossmatch, does not compromise midterm survival. The expected higher rates of rejection, especially beyond the first postoperative year, demand adjustments in surveillance strategies and immunosuppressive management.